The global blood testing market is forecasted to be worth USD 75.82 billion by 2032 and USD 61.60 billion in 2024, growing at a CAGR of 2.63% from 2024 to 2032.
Blood testing is a laboratory examination performed on blood samples taken from the patient's body with the assistance of a needle or finger pierce to determine the health situation. For instance, blood culture tests can determine the function of organs and how well healing is going on. These tests are prevalent, and even the usual check-ups might require one. Blood tests are often used in healthcare to understand biochemical and physiological states, mineral content, pharmaceutical drug effectiveness, organ function, disease, and drug tests to detect drug abuse. Multiple tests for specific blood components are often grouped into one test panel called a blood panel or blood work. In addition, blood culture tests can determine the function of organs and how well a treatment works.
According to the statistics published by Diabetes Research Clinical Practice, an estimated 463 million people have diabetes globally, estimated to reach 700 million by 2045. According to WHO, an estimated 17.9 million people die yearly from CVDs. The prevalence and incidence of these diseases are significantly growing year over year and favoring the growth of the blood testing market. The method of carrying out blood test procedures has immensely improved over the past few years, resulting in the growth of the global blood testing market. The automated method of carrying blood tests is less time-consuming and less complicated than manual techniques. So, the feasibility of automated blood test procedures will eventually help to drive market growth.
High growth in the global blood testing market can be accredited to the rising number of blood donations and donors, increasing awareness about the safety of donated blood, increasing demand for donated blood, and growing infectious diseases. The rise in the number of patients worldwide has an increased opportunity for the global blood testing market. Furthermore, the increase in people suffering from these diseases will create a better chance for market growth. In addition, many pharmaceutical and biotechnology companies provide growth opportunities for the global blood testing market.
The different kinds of blood tests available in the market for common diagnostic purposes will provide significant growth opportunities for the blood testing market growth. Furthermore, correct criteria in diagnosing significant diseases help increase revenue share and will likely have lucrative opportunities during the foreseen period.
Furthermore, factors such as high costs associated with automated blood testing, lack of awareness concerning the latest advancements, and regulatory approval processes will dampen market growth. Lack of information about the emergence of new technologies and procedures related to blood testing is another restraining factor. Patients need to be aware of the new tests or procedures available in the market to detect diseases easily. Therefore, people's lack of awareness and reluctance to adopt new technology will affect the market's growth.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2032 |
Base Year |
2023 |
Forecast Period |
2024 to 2032 |
Segments Covered |
By Type, Disease, Method, and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis; DROC, PESTLE Analysis, Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
Market Leader Profiled |
Bio-Rad Laboratories Inc. (U.S.), Siemens Healthcare (Germany), Grifols (Spain), Nanosphere Inc. (U.S.), BioMérieux (France), Dickinson and Company (U.S.), Ortho Clinical Diagnostics Inc. (U.S.) |
The complete blood count segment will lead the global blood testing market during the forecast period. The factors majorly contributing to the growth are the increasing number of blood screenings, the rising number of infectious tests, and technological advancements in counting blood cells. The Platelets sub-segment is one of the lucrative segments and is expected to register high growth during the forecast period. The growing number of blood donations and the presence of accurate and specific tests in diagnosing many diseases help drive the market successfully.
The anemia segment is projected to lead with the highest revenue share in the blood testing market due to a rising patient count suffering from lack of deficiency, a growing number of chronic diseases, and intensifying consciousness in people.
Other segments, such as Heart attack and coronary heart diseases, are predicted to hike at a healthy rate during the forecast period.
The manual blood culture testing segment is estimated to dominate the blood testing market with the largest revenue share during the forecast period. Small-sized hospitals and clinics have manual blood culture testing. In addition, the amplifying demand for point-of-care facilities for blood tests and rising demand for blood testing services propel market growth over the review period.
North America is expected to dominate the global blood testing market during the forecast period, with the U.S. being the most significant supporter. The U.S. is recognized as home to several prominent players operating in space. This, in turn, has resulted in the highest turnover in this regional market. Also, government initiatives and CLIA waivers on POC testing devices are estimated to be important factors in increasing acceptance levels for these devices in this region. The North American market is further expected to be driven by new government initiatives, developing healthcare infrastructure, increasing the number of complex surgical activities, a rise in the geriatric population, the upsurge of diseases, and technological advancements related to the market. In addition, an increase in several geriatric populations suffering from diabetes, cancer, and cardiovascular diseases will also rapidly help the blood testing market grow in the North American region.
On the other hand, the market in the Asia-Pacific region is poised to grow at a maximum CAGR during the forecast period. The growing occurrence and incidence of infectious diseases, high demand for donated blood, and improved awareness among people about the safety of donated blood propel the blood testing market in this region. In addition, the rise in the population suffering from infectious and other lifestyle diseases will help boost the market in Asia.
Europe is expected to grow at a lucrative pace due to untapped market potential and growing awareness amongst the population regarding early disease detection tests. Furthermore, increasing the number of government schemes to curb the rising healthcare expenditures in emerging economies is expected to drive regional market growth. Germany governs the blood screening industry because there is a rise in awareness about blood donation, the presence of high-quality infrastructure for hospitals and clinical laboratories, and major market players.
Latin America has been calculated at USD 5.72 billion in 2023, expected to grow at a CAGR of 2.79%. The market for blood testing continued to grow under the influence of the aging population, the rise in incidences of various diseases such as hepatitis, human immunodeficiency virus (HIV) infection, cancer, thyroids, genetic disorders, and bacterial and viral allergic disorders, and expanding application of blood testing in other diagnostic areas.
The market in MEA is expected to hold a moderate share of the worldwide market during the forecast period. A shift in healthcare provider's focus from treatment towards early exposure to diseases, particularly in cardiovascular and endocrinology medicine, has poised the industry to observe lucrative growth during the forecast period.
A few of the promising companies operating in the global blood testing market profiled in this report are Bio-Rad Laboratories Inc. (U.S.), Siemens Healthcare (Germany), Grifols (Spain), Nanosphere Inc. (U.S.), BioMérieux (France), Dickinson and Company (U.S.), Ortho Clinical Diagnostics Inc. (U.S.), Roche Diagnostics (Switzerland), Alere Inc. (U.S.), Bruker Corporation (U.S.), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.) and Beckman Coulter (U.S.)
By Type
By Disease
By Method
By Region
Frequently Asked Questions
The global blood testing market was worth USD 60.03 billion in 2023.
Geographically, the North American region dominated the market in 2023.
Based on the test type, the complete blood count segment had the major share of the blood testing market in 2023.
Bio-Rad Laboratories Inc. (U.S.), Siemens Healthcare (Germany), Grifols (Spain), Nanosphere Inc. (U.S.), BioMérieux (France), Dickinson and Company (U.S.), Ortho Clinical Diagnostics Inc. (U.S.), Roche Diagnostics (Switzerland), Alere Inc. (U.S.), Bruker Corporation (U.S.), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.) and Beckman Coulter (U.S.) are playing a significant role in the global blood testing market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region